Cancer Patients With Breakthrough COVID-19 Remain at Risk for Severe Outcomes
No significant difference observed in 30-day mortality for fully vaccinated versus unvaccinated cancer patients with COVID-19
NVX-CoV2373 Vaccine Protects Against COVID-19
Study conducted in the U.S. and Mexico shows vaccine 90 percent effective overall, 100 percent effective against moderate-to-severe disease
Omicron Cases Pass U.S. Peak Seen With Delta
However, numbers of hospitalizations have not yet reached those higher levels
More Flights Canceled as Omicron Continues to Hit Flight Crews
Several airlines acknowledge that COVID-19 contributed significantly to recent cancellations
U.S. to Lift Travel Restrictions for Southern African Countries
Omicron variant was identified first in Southern Africa
New Model Predicts Pediatric Pneumonia With Reduced X-Ray Need
Three variables in the model included age, fever duration, and decreased breath sounds
Oropharyngeal Cancer Incidence, Mortality Up Among U.S. Men
Geographic differences seen, with notable rises in the Midwest and Southeast
mRNA COVID-19 Vaccine Less Protective in Elderly With Comorbidity
At ≥7 days after second dose, effectiveness of mRNA COVID-19 vaccine was 69 percent against infection, 86 percent against related death
Three Days of Remdesivir Cuts Risk for Severe COVID-19 in Outpatients
Three-day course of treatment results in reduced risk for hospitalization or death compared with placebo
Efficacy of Bamlanivimab for COVID-19 May Vary With Antibody Status
Further study needed to determine whether bamlanivimab could benefit patients who are negative for endogenous neutralizing antibodies
